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Abstract:  Ligand-gated  ion  channels  (LGIC)  play  a  central  role  in  inter-cellular 
communication. This key function has two consequences: (i) these receptor channels are 
major targets for drug discovery because of their potential involvement in numerous human 
brain diseases; (ii) they are often found to be the target of plant and animal toxins. Together 
this  makes  toxin/receptor  interactions  important  to  drug  discovery  projects.  Therefore, 
toxins  acting  on  LGIC  are  presented  and  their  current/potential  therapeutic  uses 
highlighted. 
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1. Introduction and Scope of the Review 
1.1. To be Poisonous or Not: The Dose Effect 
When  thinking  of  toxic  compounds,  researchers  often  have  in  mind  the  famous  citation  of 
Paracelsus  (Philippus  Theophrastus  Aureolus  Bombastus  von  Hohenheim):  "The  dose  makes  the 
poison" or in its more complete version "All things are poison and nothing is without poison. Solely 
the dose determines that a thing is not a poison." [1]. Although this 16th century concept is  now 
debated, Paracelsus is still recognized as one of the fathers of "Toxicology" as it is envisioned today. 
Medical drugs and toxins are good illustrations of this adage. On the one hand, medical drugs are 
often perceived as non-poisonous because of their potential benefit for humans. However, it is now 
well known that widely used drugs like Paracetamol or Ibuprofen can be highly toxic at relatively 
moderate  doses  [2].  On  the  other  hand,  toxins  are  generally  perceived  as  dangerous  for  humans 
because of their possible accumulation in the alimentary chain or their use as biological weapons  
(e.g.,  anatoxin-a).  However,  following  Paracelsus,  lowering  the  dose  might  allow  to  make  them  
non-toxic. Solving the issue of toxicity would pave the way to turn them into medicine. Indeed, in 
addition to their use as an invaluable source of ligands for studying structural or functional properties 
of their molecular targets [3], these molecules are now increasingly interesting to researchers for their 
use as medicine or cosmetic products [4]. 
1.2. Toxins as Biological Poisons 
The word 'toxin' was first introduced by Ludwig Brieger as a name for poisons made by infectious 
agents [5]. These biological poisons allow the organisms to survive difficult environmental situations 
where the toxins are advantageous for prey capture or defense [6]. Plant toxins (e.g., nicotine) often 
function as protection against certain animals. In animals, toxins have similar defense potential and are 
also used to capture prey. Toxicity might, however, be less directly connected with environmental 
situations as in the case of fish and shellfish that become poisonous after feeding on toxic plants or algae. 
Toxins  are  nowadays  usually  defined  as  poisonous  substances  produced  by  living  organisms 
including bacteria, microalgae, plants or fungi. We will use here this definition and therefore restrict 
ourselves to natural substances affecting an animal. 
1.3. Scope of the Review 
The knowledge of toxins acting on the ligand gated ion channels (LGIC) is dispersed and not 
homogeneous. Some toxins were isolated and chemically characterized, but poorly studied on the 
LGIC afterwards. Others found very wide applications and are frequently used in research or even as 
therapeutic intervention. This in-homogeneity could be due to the fact that the study of toxins acting 
on LGIC is the intersection of two relatively separated fields: toxinology on one hand and the study of 
the LGIC on the other hand. Another explanation is that many of the toxins described below were 
discovered and characterized (and then forgotten?), before the diverse LGIC had been identified. We 
therefore  decided  to  construct  a  list  of  toxins  targeting  the  LGIC  that  would  be  as  exhaustive  
as possible. Toxins 2011, 3                        
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This compilation of toxins targeting the LGIC should be useful as toxins constitute a relatively 
unbiased—in term of chemical space covered—source of ligand structures that can be used: (i) as a 
source  of  inspiration  for  drug  design,  as  much  as  hits  identified  from  high-throughput  screening 
experiments;  (ii)  in  structure/activity  relationship  studies;  (iii)  in  virtual  screening  studies.  The 
structure of a representative member of each family of the ligand-gated ion channels has been very 
recently solved by X-ray crystallography making these studies timely.  
2. Toxins Targeting the Ligand Gated Ion Channels 
LGIC are allosteric proteins (for a recent review on the allosteric nature of nicotinic receptors, 
see [7]). Indeed, their functioning implies that they are in equilibrium between a few states, switching 
from the resting state to an active state with an open ion-channel, and eventually a desensitized state. 
In this framework, the ligands (agonists, antagonists and allosteric modulators) act by altering the 
equilibrium, i.e., they stabilize the state for which they have the highest affinity. The endogenous 
agonist binds, by definition, in the orthosteric binding site. The other ligands, notably toxins, bind 
either at  the same site  (agonists  and competitive antagonists), or in  other binding sites  (allosteric 
modulators and non-competitive antagonists).  
LGIC are oligomeric receptors made by the association of identical or homologous subunits [8]. 
The LGIC superfamilly can be subdivided into three families depending on the number of monomers 
composing an oligomer: the pentameric, tetrameric and trimeric LGIC. 
The pentameric family encompasses the nicotinic acetylcholine receptors (nAChRs; ʱ1-10, β1-4, γ, 
δ, ε), the Gamma-aminobutyric acid (GABA) receptors (ʱ1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) receptors, 
the Serotonin (5-hydroxytryptamine, 5HT3) receptors (5-HT3A-E) and the Glycine receptors (ʱ1-3, β) 
[9,10]. The endogenous agonist binding site lies at the interface between subunits (Figure 1). The 
location of alternative binding sites has been identified at homologous interfaces (e.g., benzodizepines 
for the GABA receptors) and in the transmembrane domain [11].  
The tetrameric family of LGIC consists of glutamate receptors. This LGIC family contains the  
ʱ-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors (GluA1-4), kainate receptors 
(GluK1-5)  and  N-methyl  D-aspartate  (NMDA)  receptors  (GluN1,  GluN2A-D,  GluN3A-B).  The 
agonist binding site of tetrameric LGIC lies inside monomers (Figure 2). The agonists and alternative 
binding sites are known from biochemical and structural studies [12]. 
The trimeric family of LGIC is made by P2X receptors (P2X1-7). The knowledge of the binding 
site is much more restricted compared to that of pentameric and tetrameric LGIC: the binding site for 
ATP has been tentatively localized in a cavity at the interface between subunits (Figure 3). 
Below are listed selected toxins, known to act on the various LGIC, that are important for historical 
or pharmacological reasons. This series of toxins is complemented by a list presented as an appendix 
(Section 5). Toxins 2011, 3                        
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Figure 1. Structure of pentameric ligand-gated ion channels (LGIC). Muscle type nAChR 
is taken as an example. Top left: Topology of the receptor. Top right: Top view  of the 
receptor. Bottom left: Side view of the receptor showing the extracellular, intracellular and 
transmembrane  domains. Agonist  binding  sites  are  located  at  subunit  interfaces  in  the 
extracellular side of the receptor. Bottom right: Longitudinal cross section of the receptor, 
showing the pore domain. 
 
2.1. Nicotinic Acetylcholine Receptors 
Nicotinic receptors are arguably the most well-known LGIC to date. This is probably due to their 
very early discovery and the large number of toxins blocking them. Historically, the pharmaceutical 
knowledge  of  the  cholinergic  system  has  emerged  with  the  ―discovery‖  of  curares  by  Spanish 
explorers in South America during the 16th century. Indeed, curares were used there by local tribes for 
hunting [1]. It was found during the 19th century that curares block the synaptic transmission at the 
level of the neuromuscular junction [13] therefore paralyzing the prey. Similar usage of curares have 
also been reported in Africa [14], and Malaysia [15]. Toxins had an invaluable contribution to the 
emergence of the notion of LGIC as nAChR where first defined as the ―nicotine and curare receptive 
substance‖ [16]. Toxins 2011, 3                        
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Figure 2. Structure of tetrameric LGIC. NMDA receptor is taken as an example. Top left: 
Topology of the receptor. Top right: Top view of the receptor. Bottom left: Side view of the 
receptor  showing  the  extracellular,  intracellular  and  transmembrane  domains.  Agonist 
binding  sites  are  located  in  juxta-membrane  domains  in  the  extracellular  side  of  the 
receptor.  Bottom  right:  Longitudinal  cross  section  of  the  receptor,  showing  the  
pore domain. 
 
Another historically significant toxin targeting the nAChR is -Bungarotoxin (reviewed in [17]). It 
was  first  used  to  isolate  the  nAChR  [18,19]. The  venoms  of  marine  cone  snails  represent  a  rich 
combinatorial-like library of evolutionarily selected, neuropharmacologically active peptides called 
conotoxins (Figure 4, Table 1) that target  a wide variety of receptors and ion-channels [20]. The 
subtype  specific  snake  -neurotoxins  and  cone  snail  -conotoxins  are  still  widely  used  to  probe 
receptor structure and function in native tissues and recombinant systems [21]. 
Nicotine is a highly toxic alkaloid proposed to serve as an insecticide protecting Tobacco plants 
[22].  It  is  the  prototypical  agonist  at  nicotinic  cholinergic  receptors  (Figure  5)  in  comparison  to 
muscarinic receptors [23]. Tobacco extract was used as an insecticide for centuries [24], perhaps as 
early  as  1690  [25].  The  effect  relies  on  the  presence  of  nicotine  and  anabasine  (see  Section  5). 
Moreover, nicotine and anabasine were still in use in the early 20th century (see below). Nicotine is 
also important medically because it is thought to be responsible for tobacco addiction through the 
stimulation of  nAChR on dopaminergic neurons of the ventral tegmental area (VTA) [26]. Toxins 2011, 3                        
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Figure 3. A schematic view of trimeric LGIC (P2X receptor). Top left: Topology of the 
receptor.  Top  right:  Top  view  of  the  receptor.  Bottom  left:  Side  view  of  the  receptor 
showing the extracellular, intracellular and transmembrane domains. Agonist binding sites 
are  presumably  located  at  subunit  interfaces  in  the  extracellular  side  of  the  receptor. 
Bottom right: Longitudinal cross section of the receptor, showing the pore domain. 
2. 
Figure 4. Representative protein toxins targeting the nicotinic acetylcholine receptors. 
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Table 1. -conotoxins acting on nAChRs. 
Name  Conus specie  Target  References  
GI, GIA, 
GII 
geographus  Muscle nAChR  [27] 
MI  magus  Muscle nAChR  [28] 
SI, SIA and 
SII 
striatus  Selectivity for the distinct interfaces (or 
 of the muscle-type nAChR 
[28,29] 
ImI, ImII  imperialis  Selective for 7 nAChR but also effective 
on 
[30] 
BuIA   bullatus  Highest potency for - and containing 
nAChRs 
[31] 
CnIA, CnIB   consors  Muscle nAChR  [32] 
Ac1.1a, 
Ac1.1b 
achatinus  Muscle nAChR  [33] 
EI  ermineus  Selective for muscle nAChR, also effective 
on 
[34] 
PnIB, 
(A10L)-
PnIA 
pennaceus  Selective for  nAChR  [35,36] 
GIC  geographus  Selective for  [37] 
MII   magnus  Selective for  nAChR  [38,39] 
PIA   purpurascens  Selective for 

[40] 
PIB  purpurascens  Muscle nAChR  [41] 
GID  geographus   [42,43] 
AuIA, AuIB 
and AuIC  
aulicus  Selectively blocks nAChRs  [44] 
EPI   episcopatus  Selective for  [45,46] 
AnIB  anemone   [47] 
Vc1.1  victoriae   [48,49] 
ArIA, ArIB  arenatus  

[50] 
PeIA  pergrandis   [51] 
OmIA  omaria   [52] 
TxIA  textile   [53] 
Lp1.1  leopardus   [54] 
SrIA, SrIB  spurious  , muscle type nAChRs  [55] 
-Erythroidine  is  isolated  from  the  coral  tree  Erythrina  crista-galli.  It  acts  as  a  competitive 
antagonist of nicotinic receptors (it targets and ʱ3β2* receptors and has weak affinity for 
the muscle type and ʱ3β4) [56]. At high concentrations, they are noncompetitive blockers of possibly 
all nicotinic receptors subtypes [57–59]. Erysodine is a structurally related Erythrina Alkaloid acting 
on and ʱ3β2* nAChR. Both compounds are weak binders to 7 nAChR explaining that they are 
used to discriminate between different nAChR subtypes although they are relatively non-selective. Toxins 2011, 3                        
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Figure  5.  Representative  alkaloids  targeting  the  nicotinic  acetylcholine  receptors.  
Top: agonists, middle: competitive antagonists, bottom; non-competitive antagonists. 
 
Methyllycaconitine (MLA), is extracted from Delphinium species [60] and is a potent and highly 
selective ʱ7 nAChR antagonist [61,62]. MLA is largely used for this property as a pharmacological 
tool in research [63]. MLA together with additional alkaloids in Delphinium species (nudicauline,  
14-deacetylnudicauline, barbinine and deltaine) have also been found to act on nAChRs blocking 
the neuromuscular junction which may be related to the Delphinium species involvement in cattle 
poisoning [64,65]. Toxins 2011, 3                        
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2.2. GABA-A Receptors 
The  toxins  of  the  GABA  receptors  are,  as  for  the  nAChR,  of  different  categories  (agonists, 
antagonists and allosteric modulators) as illustrated by the examples described below. 
-thujone is extracted from the wormwood Artemisia absinthium and is found in absinthe [66]. It 
is a negative allosteric modulator of GABA-A receptors (Figure 6) resulting in convulsant activity 
[67]. -thujone also antagonizes 5HT3 receptors [68]. 
Figure 6. Representative toxins targeting the GABA receptors. 
 
Bicuculline, isolated from Dicentra cucullaria, is a competitive antagonist of GABA-A receptors 
causing convulsions [66].  
Muscimol is an agonist extracted from Amanita muscaria partly responsible for the toxic effect of 
the mushroom [66]. 
Picrotoxin is a non-competitive antagonists isolated from Menispermaceae. Binding modes for 
picrotoxin have been proposed in the ion channel [69–71]. 
2.3. Glycine Receptors 
Strychnine is found in the seeds of the Strychnine tree (Strychnos nux-vomica). Strychnine causes 
muscular  convulsions  and  eventually  death  through  asphyxia  or  sheer  exhaustion.  It  is  used  as  a 
pesticide, particularly for killing small vertebrates such as birds and rodents. Strychnine participates in 
the pharmacological differentiation of receptors responsive to glycine. Indeed, some NMDA receptors 
are also activated by glycine but are strychnine insensitive [72]. 
2.4. Serotonin Receptors 
The serotonin receptors have very few known toxins: Conotoxin GVIIA (-conotoxin; a large 41 
amino-acids conotoxin [73]) and d-tubocurarine. Toxins 2011, 3                        
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d-Tubocurarine  is  a  mono-quaternary  alkaloid  obtained  from  the  bark  and  stems  of 
Chondrodendron tomentosum. d-Tubocurarine blocks nAChRs at the neuromuscular junction but also 
acts on serotonin receptors [74]. d-Tubocurarine is the archetypal curare. As neuromuscular blockers, 
curares can be used as skeletal muscle relaxants and were indeed introduced in anesthesia in 1942 [75]. 
Curares are active only by injection. They are harmless if taken orally because curare compounds are 
too large and too highly charged to pass through the lining of the digestive tract to be absorbed into the 
blood. This explains how they can be used to kill prey that will be later ingested.  
2.5. NMDA Receptors 
Ageltoxin (agatoxin) are arylamine toxins (the  -agatoxins) found in the venom of the spider 
Agelenopsis aperta. They paralyze insects by blocking glutamatergic neuromuscular transmission [76]. 
Ageltoxins are thought to be non-competitive channel blockers specific for NMDA receptors [76,77]. 
Conantokins are found in the venom from Conus fish hunting snails [78]. The conantokins (G, L, R 
and T)  form  a  class  of  peptides  that  inhibit  competitively  NMDA  receptors  [79,80].  Interestingly 
conantokins possess a large number of -carboxyglutamic acid residues (Figure 7) [81]. One of the 
carboxyglutamic acid residues is thought to participate in the selectivity of conantokin G [82]. 
2.6. AMPA Receptors 
Quisqualic acid is isolated from the seeds of Quisqualis indica. Quisqualic acid is an agonist at 
AMPA receptors [83]. Quisqualate used to be the prototypical ligand of AMPA receptors, which were 
therefore called quisqualate receptors. However, this name has been abandoned as quisqualate also acts 
at metabotropic glutamate receptors [83]. 
2.7. Kainate Receptors 
Kainic acid was first isolated from the red alga Digenia simplex, where it might play a defense 
role, [84] and is also found in other algae [85]. Kainic acid is the prototypical agonist defining the 
Kainate subtype of glutamate receptors. The toxin is associated with human poisoning through the 
consumption of mussels that eat the algae. 
2.8. P2X Receptors 
Purotoxin are P2X receptors modulators which were isolated from the venom of the wolf spider 
Geolycosa sp [86]. Later, purotoxin has been isolated and shown to be a non-competitive antagonist of 
the P2X3 receptors [87]. It was found to be a close homologue to other spider toxins of unknown 
function and a more distant homologue to toxins known to bind to other receptors [87]. However, none 
of the receptors tested, besides P2X3, were sensitive to purotoxin, which makes it to date the only 
toxin specific of P2X receptors [87]. Toxins 2011, 3                        
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Figure 7. Representative toxins targeting the glutamate receptors. Top: NMDA receptors; 
Middle: AMPA receptors; Bottom: Kainate receptors. 
 
3. Current and Proposed Medical Use of Toxins Targeting the LGIC 
Neurotoxins are great sources of medicine or cosmetic products [4]. In addition to their usage as 
analgesics [79], they are now evaluated as potential treatment for many pathologies [4,6,88]. The 
toxins presented below are those that are used in clinic or that entered clinical trials (clinical trials were 
monitored using the website clinicaltrial.org). However, for some LGICs, no toxin has reached clinical 
trials.  Therefore,  this  section  is  also  complemented  with  information  from  patents  and  recent 
preclinical data. 
An important characteristic of all the toxins presented below is that they are not used as alternative 
strategies  because  of  toxic  properties  [89].  Instead,  the  toxins  targeting  LGIC  are  used  for  their 
modulating activity. 
3.1. nAChR 
The nAChR has the largest number of known toxins (Sections 2 and 5). It is probably not surprising 
that nAChR also has the largest number of toxins used medically. Interestingly, both agonists and 
antagonists are used differently to what is observed for most of the other LGIC. 
3.1.1. Agonists 
nAChR agonists are considered for their central action and, beyond treatment of tobacco addiction, 
the main targeted effect is cognition stimulation.  
Three agonists are used to treat tobacco dependence: Cytisine (in eastern and central Europe) [90], 
Lobeline [91] and Nicotine. Toxins 2011, 3                        
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nAChR  agonists  are  also  considered  in  the  treatment  of  neurological  disorders.  Nicotine  is 
evaluated for Parkinson‘s disease (phase II), schizophrenia (phase IV), sarcoidosis (phase IV) and pain 
(phase  IV).  Lobeline  is  evaluated  for  therapeutic  intervention  in  Attention  Deficit  Hyperactivity 
Disorder (phase II). Epibatidine has been evaluated for the treatment of pain in phase II clinical trials 
(as ABT-594) and later abandoned because of adverse effects [4]. GTS21 (derived from anabaseine) is 
evaluated (phase II) for therapeutic intervention against schizophrenia [92].  
3.1.2. Competitive Antagonists 
Curares derived from d-tubocurarine are widely used for local anesthesia as myo-relaxant. The 
curare pancuronium is also used for enforcing the death penalty. The reader is referred to the review of 
Norman Bisset [1] for a historical perspective on the use of curares.  
Cobratoxin is used in traditional medicine in China [93] and India. Cobratoxin use has also been 
proposed  for  the  treatment  of  small  and  non-small  cell  lung  cancer  by  blocking  the  7  nAChRs  
[94–98]. Cobratoxin has also been proposed for the treatment of pain [99] and Multiple sclerosis [100]. 
In terms of the latter pathology, a chemically attenuated version of cobratoxin [101], also known as 
receptin or RPI-78M, is under investigation in a phase II clinical trial. 
Conotoxins  hold  a  significant  therapeutic  potential  that  has  been  reviewed  recently  [3,4]. 
-conotoxin  Vc1.1,  which  targets  AChRs,  has  been  tested  in  a  phase  II  clinical  trial  
(as ACV1) but the development was later discontinued. It should be noted that -conotoxin Vc1.1 has 
been proposed to target also the N-type calcium channel [102–104]. Muscle-selective ʱ-conotoxins  
(e.g.,  ʱ-GI),  could  represent  an  alternative  to  the  use  of  small  molecule  curare-mimetic  muscle 
relaxants, which are used during surgery, but have slower than ideal recovery period [4,105]. 
3.1.3. Non-Competitive Antagonists 
Strychnine used to be prescribed for the treatment of myasthenia until 1930 [106]. ―Myasthenia‖, 
however, encompass very diverse pathologies that were not discriminated before the 20th century 
[107]: (i) Myasthenia gravis is an autoimmune disease [107]; (ii) congenital myasthenia syndromes are 
associated with genetic alterations, some of them increasing or decreasing nAChR response to ACh 
[108]. Using an antagonist like strychnine cannot be beneficial to treat cases of reduced cholinergic 
signaling. Such a treatment could only be beneficial for the cases displaying an increased activity of 
the nAChR, i.e., the slow channel congenital myasthenia. Interestingly, quinidine, which acts as a non 
competitive antagonist—strychnine has a similar effect on muscle nAChR [109]—is used nowadays to 
treat patients with slow-channel congenital myasthenia. 
Mecamylamine  is  a  drug  introduced  in  the  1950s  as  an  anti-hypertensive  agent  and  is  now  
(as TC5214) under clinical trials (phase III) for the treatment of Major Depressive Disorder. 
3.2. Other Pentameric Ligand Gated Ion Channels 
None of the toxins targeting the other pentameric LGIC (GABA, Glycine, Serotonin) have been 
used  in  medical  practice.  Furthermore,  none  of  the  toxins  targeting  these  receptors  has  entered  
clinical trials.  Toxins 2011, 3                        
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For GABA receptors, a patent proposes the use of either the agonist muscimol or the antagonist 
bicuculine for the treatment of myopia. Numerous, synthetic compounds targeting the GABA receptors 
are on the market, the most significant being barbiturates and benzodiazepines. These compounds act 
by increasing the mean open time of the ion channel. 
Among synthetic compounds, anesthetics (e.g., propofol) potentiate Glycine receptors. However, 
propofol also acts on GABA receptors. Currently, no drug targets specifically Glycine receptors [110]. 
The amino-acid taurine, found in energizing sodas is an inhibitor of the Glycine receptor [111]. 
Synthetic antagonists targeting the Serotonin receptors are used as antiemitic drugs [112]. Similarly, 
natural compounds targeting the Serotonin receptors have antiemitic properties, e.g., ginger extracts 
and delta-9-tetrahydrocannabinol from Cannabis sativa. 
3.3. NMDA Receptors 
Toxins targeting the NMDA receptors (Figure 7, top) have neither been used medically nor tested 
clinically. Synthetic  compounds targeting the  NMDA  receptors in clinical  use  are mainly channel 
blockers (Ketamine, Memantine, Amantadine) but also antagonists (Felbamate) [113]. Partial agonists 
have also been tested clinically (GLYX-13 and Acomposate). 
Conantokins G and T have been noticed to display antinociceptive [114,115] and anti-epileptic 
properties [4,116]. Some conantokins demonstrate receptors subunit selectivity, which makes them 
attractive drug candidates [117]. 
Domoic acid containing algae are used as vermifugal agents in Japanese traditional medicine [118]. 
3.4. AMPA Receptors 
Toxins targeting the AMPA receptors (Figure 7, middle) have neither been used medically nor tested 
clinically. The only drug on the market targeting AMPA receptors is the potentiator Aniracetam (in 
Italy  and  Greece).  Drugs  targeting  the  AMPA  receptors  that  entered  clinical  trials  were  either 
antagonists (e.g., E2007/perampanel advanced in phase III) or positive allosteric modulators.  
3.5. Kainate Receptors 
Kainic  acid  is  used  in  Chinese  and  Japanese  traditional  medicines  as  an  anthelmintic  to  treat 
ascarialis [118]. Kainic acid is the only toxin targeting the kainate receptors (Figure 7, bottom) used as 
a treatment, and none have been tested clinically. 
3.6. P2X 
No drug targeting P2X receptors is on the market yet [119] and only very few clinical trials have 
been performed on that target (CE-224535 and GSK-1482160, which are not toxins). This observation 
can  probably  be  explained  by  the  very  recent  discovery  of  this  family  of  LGIC.  However,  P2X 
receptors are attracting a lot of interest from pharmaceutical companies as shown by the significant 
number of patents filled recently [120]. All of the compounds proposed to target P2X receptors are 
antagonists. In agreement with this observation, among toxins targeting the P2X receptors (Figure 8), Toxins 2011, 3                        
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Purotoxin has been proposed for the treatment of pain based on the observation of antinociceptive 
activity in animal testing [87]. 
Figure 8. Representative toxins targeting P2X receptors. 
 
4. Conclusion 
One significant observation made during the preparation of this review is that the number of toxins 
acting on each family of LGIC is highly variable, ranging from a large number acting on nAChR to 
little acting on others like P2X receptors (see Sections 2 and 5). Two biological explanations can  
be proposed: 
Although LGIC are mainly considered for their role at synapses they are also found in organisms 
that do not have any synapse [121]. Indeed, homologous proteins have been found in prokaryotes for 
pentameric [122,123] and tetrameric [124] LGIC but are still to be found for P2X receptors. It can 
therefore  be  proposed  that  P2X  receptors  appeared  more  recently  in  evolution  and  that  the  early 
emergence of pentameric and tetrameric LGIC could have allowed more time for toxin co-evolution. 
The physiological roles of the diverse LGIC could also play a role in the imbalance in the number 
of toxins targeting the LGICs. Indeed, nAChRs, which are largely targeted by toxins, have a prominent 
role at the neuromuscular junction and, as mentioned above, numerous toxins target that function. 
Glutamate receptors are also involved in the neuromuscular transduction in invertebrates [125]. In 
comparison, the role of P2X receptors at the neuromuscular junction is limited in that it does not 
participate  directly  in  the  transmission,  but  in  the  neuro-muscular  junction  development  and 
regeneration [126], and should therefore be a less critical target for prey capture. 
In addition to these biological explanations, the asymmetry in the knowledge of toxins targeting 
LGIC could also be due to the lack of research on the latter identified P2X receptors compared to the 
first identified nicotinic receptors. Indeed, the targeted receptor is not necessarily obvious from the 
symptoms and specificity of action may come from other reasons than pharmacological ones,  i.e., 
many toxins can affect receptors present in the CNS whereas they do not reach them physiologically. Toxins 2011, 3                        
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The known interactions therefore largely depend on specific studies on the effect of toxins on LGIC 
that are themselves asymmetric. 
Given the therapeutic potential of toxins, this observation makes the quest for new toxins targeting 
P2X receptors an attractive area of research. 
Appendix: List of Toxins Targeting the LGIC 
1. Nicotinic Acetylcholine Receptors 
1.1. Peptides and Proteins 
1.1.1. Conotoxins 
-conotoxins  (Table  1)  constitutes  the  largest  group  of  conotoxins  that  target  muscle  nAChRs 
and/or specific subtypes of neuronal nAChRs in mammals [29]. -conotoxins can distinguish amongst 
different subunit arrangements and therefore represent valuable pharmacological tools for research and 
hold therapeutic promises [127]. 
Table 1. -conotoxins acting on nAChRs. 
Name  Conus Specie  Target  References 
GI, GIA, GII  geographus  Muscle nAChR   [27] 
MI  magus  Muscle nAChR   [28] 
SI, SIA and SII  striatus  Selectivity for the distinct interfaces (or  of the 
muscle-type nAChR 
 [28,29] 
ImI, ImII  imperialis  Selective for 7 nAChR but also effective on    [30] 
BuIA  bullatus  Highest potency for - and containing nAChRs   [31] 
CnIA, CnIB   consors  Muscle nAChR   [32] 
Ac1.1a, Ac1.1b  achatinus  Muscle nAChR   [33] 
EI  ermineus  Selective for muscle nAChR, also effective on    [34] 
PnIB, (A10L)-PnIA  pennaceus  Selective for  nAChR   [35,36] 
GIC  geographus  Selective for    [37] 
MII   magnus  Selective for  nAChR   [38,39] 
PIA   purpurascens  Selective for    [40] 
PIB  purpurascens  Muscle nAChR   [41] 
GID  geographus    [42,43] 
AuIA, AuIB and AuIC  aulicus  Selectively blocks nAChRs   [44] 
EPI   episcopatus  Selective for    [45,46] 
AnIB  anemone    [47] 
Vc1.1  victoriae    [48,49] 
ArIA, ArIB  arenatus    [50] 
PeIA  pergrandis    [51] 
OmIA  omaria    [52] 
TxIA   textile    [53] 
Lp1.1   leopardus    [54] 
SrIA, SrIB  spurious , muscle type nAChRs   [55] Toxins 2011, 3                        
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-conotoxins selectively antagonize the foetal subtype of the mammalian neuromuscular nAChR. A 
few have been identified: AS OIVA and OIVB (from C. obscures), AS PeIVA and AS PeIVB 
(from C. pergrandis), A PIVA (from C. purpurascens), A EIVA and A EIVB (from C. ermineus), 
C PrXA (C. parius), or S RVIIIA (C. radiates). 
Non--conotoxins act on muscle-type nAChRs. -conotoxin PIIIE (from C. purpurascens) has a 
structure similar to that of the voltage-gated Na+ channel-blocking -conotoxins and acts as a non-
competitive antagonist (perhaps a pore blocker) of the muscle-type nAChR [44]. -conotoxin PIIIF 
has also been identified in C. purpurascens and -PrIIIE in C. parius. 
1.1.2. Snake Neurotoxins 
Snake  neurotoxins  have  the  same  neuromuscular  blocking  effects  than  the  plant  alkaloid  
(+)-tubocurarine, but with approximately 15–20-fold greater affinity and poor reversibility of action. They 
are  referred  to  as  curaremimetic  neurotoxins  or  postsynaptic  neurotoxins  (Table  2).  Snake  venom  
-neurotoxins are polypeptides of 60–74 amino acid residues with 4-5 disulfide bridges, divided as short- 
(60–62 amino acids, 4 disulphide bridges) and long-chains (66–75 amino acids, 5 disulphide bridges). 
Table 2. Snake neurotoxins acting on nAChRs. 
Name  Source  Target  Structural Group  References 
-Bungarotoxin  Bungarus 
multicinctus 
Muscle,  Long-chain -neurotoxin   [128,129] 
NmmI  Naja mossambica 
mossambica 
Muscle  short-chain -neurotoxin   [130]
bungarotoxins  Bungarus genus   and other 
2-containing 
nAChRs. 
long-chain neurotoxin   [131]
-cobratoxin  Naja genus  
(e.g., Naja 
kaouthia) 
Muscle,  long-chain -neurotoxins   [132] 
Erabutoxin-a.  Laticauda 
semifasciata 
Muscle  Short-chain -toxin   
erabutoxin-b  Laticauda 
semifasciata 
Muscle  short-chain neurotoxin   [133] 
Toxin- Naja nigricollis  Muscle  short-chain -neurotoxin   
The human protein Lynx1 has been proposed to be evolutionary related to snake venom toxins 
[134,135]. It binds tightly to nAChRs and inhibits their activation. It has been shown that Lynx1 both 
decreases nAChR sensitivity to ligands and increases desensitization. 
Denmotoxin  is  present  in  the  venom  from  the  Colubrid  snake  Boiga  dendrophila  (Mangrove 
Catsnake). It displays remarkable species specificity, being able to interact irreversibly and with high 
affinity with chick muscle nAChR, but only with low affinity with mouse nAChR [136]. 
Waglerins are polypeptide isolated from the venom of South Asian snake Tropidolaemus wagleri 
consisting of 22–24 amino acids and containing one disulfide bridge. These toxins interact with high 
affinity with muscle-type nAChR [137]. Toxins 2011, 3                        
 
276 
Weak neurotoxins form the group of three fingered toxins consisting of 62-68 amino acid residues 
with five disulfide bridges characterized by low toxicity. Toxins of this type were later referred to as 
melanoleuca or miscellaneous-type or non-conventional toxins (Table 3). They bind to neuronal as 
well as Torpedo nAChRs, although with low (micromolar) affinities [138]. 
Acanthophin is found in death adder venoms; they are rich in a diversity of ‗short-chain‘ and 
‗long-chain‘ postsynaptic neurotoxins that bind to nAChR in skeletal muscle and produce facial and 
bulbar paralysis. 
1.1.3. Natural Toxic Peptides from Other Species 
Philanthotoxin is found in the venom from the Egyptian digger wasp Philanthus triangulum and 
acts both as competitive and noncompetitive antagonist [148]. 
Huwentoxin  is  a  neurotoxic  peptide  purified  from  the  venom  of  the  Chinese  bird  spider 
Selenocosmia huwena. This family consists of several types. Huwentoxin-1 is a lethal neurotoxin that 
binds to  the nAChR and blocks neuromuscular transmission. Huwentoxin-2 blocks neuromuscular 
transmission and acts cooperatively to potentiate the activity of Huwentoxin-I [149,150]. 
Table 3. Weak neurotoxins acting on nAChR. 
Name  Origin  Target  Other specifications  References 
Candoxin  Bungarus candidus  7 and muscle.     [139] 
CM-11, CM-2  Naja haje haje 
(Egyptian cobra) 
Muscle     [140] 
CM10, CM12, 
CM-13b, CM-14 
Naja haje annulifera  Neuromuscular 
Junction 
   [141] 
Cm-9a  N. kaouthia       
S4C11   N. melanoleucaI.    neurotoxin 
Homologue 
 [142] 
S5C1, S5C10  Dendroaspis jamesoni 
kaimosae (Eastern 
Jameson's mamba) 
Muscle     [143] 
S6C4  Dendroaspis jamesoni 
Kaimosae (jameson‘s 
mamba) 
  67% sequence identity 
with Bucandin. 
 
-bungarotoxin  Bungarus multicinctus  post synaptic 
action 
   [144] 
WTX   Naja kaouthia  7 and muscle.     [138] 
Wntx-5   Naja sputatrix  Torpedo 
chick 
   [145] 
NNA2   the Taiwan cobra (N. 
n. atra) 
Muscle  long-neurotoxin 
homologue 
 [146] 
LSIII  Laticauda 
Semifasciata 
neuromuscular 
blockade 
   [147] 
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1.2. Alkaloids 
Cytisine from the golden chain tree is a natural agonist of nicotinic α4β2/α3β4*/α7 receptors. Other 
Cytisine-like analogs are caulophylline and tinctorine [151].  
Comparing Nicotine with cytisine and caulophylline allowed drawing attention on the effect of pKa 
on activity [152]. This observation, in turn, paved the way for the proposal that alkaloids bind through 
a cation/pi interaction with aromatic residues present in the nAChR orthosteric binding site. 
Anatoxin-a is a natural agonist produced by diverse cyanobacteria throughout the world [153]. 
Anatoxin-a is a cyanotoxin considered as an environmental issue as it is found in water bodies and 
promotes animal deaths [154]. In addition, given that intoxication due to anatoxin-a is possible from 
drinking water it has been considered that it could be used as biological weapon. For all those reasons 
numerous  detection  methods  have  been  developed  [155].  Anatoxin-a  has  nanomolar  affinities  for 
* and  homoanatoxin.  
Epibatidine  is  a  potent  nicotinic  agonist  from  Dendrobatid  frog  (Epipedobates  tricolor)  with 
antinociceptive properties [156]. Epibatidine has selectivity for  >  >  > 
Other nicotinic alkaloids from Epipedobates tricolor are N-methylepibatidine, Epiquinamide and 
nicotine. Epiquinamide is selective for nicotinic receptors containing the β2-subunit. 
Anabasine  is  found in  various  natural  sources  like plant Nicotiana  glauca, ant  Aphaenogaster 
fulva, marine worm Paranemertes Peregrina. Anabaseine is an agoinst for   and  nAChR. 
Anabaseine which is a potent agonist on muscle and neuronal  -Bungarotoxin-sensitive nicotinic 
receptors [157], is found in tobacco and is also present in small amounts in tobacco smoke. Anabasine 
has been used as an insecticide. 
Histrionicotoxin  is  a  toxin  isolated  from  skin  secretions  of  a  Colombian  frog,  Dendrobates 
histrionicus. It is a potent non-competitive antagonist of nAChR. More than 100 toxins have been 
identified  from  the  skin  secretions  of  members  of  the  Dendrobatidae  family  of  frogs,  especially 
Dendrobates and Phyllobates. Members of the genus Dendrobates (of which there are at least 44 
known species) are also known as "poison dart" or "poison arrow" frogs [158]. 
Ferruginine is a rather weak agonist of neuronal type nAChR from plant Darlingia ferruginea, 
other analogs include darlingine [159]. 
Carbamylcholine like acetylcholine activates both nicotinic and muscarinic receptors. The affinity 
for nicotinic receptors is in the order of  >  > 
Toxiferines are isolated from Strychnos species. C-toxiferine I (also refered to as toxiferine) is a 
quaternary alkaloids and, like tubocurarin, is a curare that acts as a competitive antagonist for nicotinic 
receptors, but is relatively nonselective. They were first found very potent to block the neuromuscular 
junction [160]. Toxiferine I, among neuronal type nAchR tested was found to bind mainly on  7 
subtype [161]. Toxiferines were first used in anesthesia but were abandoned later because their effect 
was prolonged over too long periods [162]. 
Neosurugatoxin, a complex alkaloid glycoside isolated from a mollusk, Babylonia japonica [163], 
is a potent nicotinic competitive antagonist which blocks both muscle and neuronal nAChR [3,164–166]. 
Ibogaine is found principally in the west african Tabernanthe iboga were it is used in ceremonies of 
the Bwiti religion [167]. It was used for its anti-addictive properties but was later banned for being Toxins 2011, 3                        
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addictive [167]. It is a noncompetitive blocker of nicotinic receptors [168], and also interacts with 
other proteins including NMDA receptors [167].  
Strychnine is a non-competitive antagonist at  receptors but acts as a competitive antagonist at 
 receptors [169]. 
Coaine  is  found  in  the  plant  source  Erythroxylon  Coca  and  is  is  a  noncompetitive  blocker  in 
particular for   α7-selective 
agonist [170]. 
Sparteine, a lupin alkaloid extracted from Lupinus luteus, has been found to be an antagonist for 
 receptors. Lupin alkaloids are found in wide variety of plants around the world and are generally 
toxic [171,172]. 
Parazoanthoxanthin A  is  a  fluorescent  pigment  of  the  group  of  zoanthoxanthins.  It  has  been 
shown that Parazoanthoxanthin A demonstrates a dual  action on  Torpedo nAChR;  both  as  a pore 
blocker and a competitive antagonist [173]. 
1.3. Others 
Lophotoxin  from  various  Pseudopterogorgia  species,  gorgonian  soft  corals,  is  a  potent  and 
irreversible  antagonist  for  neuromuscular-type  nicotine  receptors  [174–177].  Lophotoxin  appears 
selective towards ʱ4β2 and ʱ1β1γδ nicotinic receptors [178]. It was found to react with Trp 190 in the 
-subunit [179]. Its analogue Bipinnatin B has similar properties [180].  
Luffarins (K, L and R) as well as Comentins (A, B and C) are non-specific antagonists extracted 
from Australian soft corals [3]. 
2. GABA-A Receptors 
Cicutoxin from the leaves of Cicuta virosa causes convulsion and respiratory paralysis [181]. 
Cunaniol from the leaves of Clibadium sylvestre a GABAA antagonist is a potent convulsant [181]. 
Ethanol is a positive modulator of GABA receptors [181]. 
3. Glycine Receptors 
Brucine is a plant alkaloid found in several species, most notably the Strychnine tree (Strychnos 
nux-vomica L.). Brucine is structural related to strychnine. 
Tutin is a plant toxin found in the tutu plant (genus Coriaria). It has powerful convulsant effects.  
4. Serotonin Receptors 
The serotonin receptors have very few known toxins: Conotoxin GVIIA (-conotoxin; a large 41 
amino-acids conotoxin [73]) and d-tubocurarine (see nAChRs). 
5. NMDA 
Ibogaine see nAChR. 
Ibotenic  acid  was  first  isolated  from  the  fungus  Amanita  ibotengutake  [182,183].  The  fungus 
Amanita muscaria (fly agaric) got its name from its poisonous actions on flies [184]. Toxins 2011, 3                        
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Kaitocephalin  was  isolated  from  the  fungus  Eupenicillium  shearii  as  a  glutamate  receptor 
antagonist, which protected from kainate toxicity [185]. 
Kaitocephalin was latter found to be an antagonist of NMDA and AMPA receptors and also a weak 
antagonist of the KA-type receptor GluK2 [186]. 
Phoneutriatoxin is isolated from the spider Phoneutria nigriventer. It was found to have effect on 
Glutamate uptake [187,188] and to be specific of NMDA receptors [189]. 
6. AMPA 
DABA  (2,4-diaminobutyric  acid)  and  BOAA  (beta-N-oxalylamino-L-alanine)  are  found  in  the 
seeds of the flat pea Lathyrus sylvestris. Both DABA and BOAA are excitatory neurotoxins acting on 
the AMPA-type receptors [184]. 
Philanthotoxins  (alpha,  beta,  gamma,  delta)  were  first  isolated  from  the  wasp  Philanthus 
triangulum. philanthotoxin blocks glutamate receptors [190], both AMPA [191] and kainate [192]. 
Philanthotoxin forms the class of polyamine toxins with argiotoxin, Joro spider toxin and agatoxin. 
Polyamine toxins are non-competitive antagonist binding probably at the ion channel [193]. 
Argiotoxins were first isolated from the spider Argiope lobata [194]. Argiotoxin is an inhibitor of 
NMDA and kainate receptors [195]. 
Joro spider toxin was isolated from the Joro spider Nephilia clavata [196]. Joro spider toxin shows 
analgesic properties [197]. 
Willardiine  was  first  isolated  from  seeds  of  Acacia  willardiana  [198]  and  latter  from  Acacia 
lemmoni, Acacia millefolia, and Mimosa asperata [198]. Willardiine acts as an agonist on the AMPA 
and kainate receptors [199]. 
7. Kainate Receptors 
Kainic acid is the first membre of the Kainoids familly of molecules that also encompass notably 
Domoic acid and acromelic acid. Acromelic acids (A, B and C) are found in the poisonous mushroom 
Clitocybe acromelalga [200]. Domoic acid was originally isolated from the red alga Chondria armata 
and was found in the genus Pseudonitzschia and the species Nitzschia navis-varingica. Domoic acid is 
associated  with  Amnesic  shellfish  poissoning  [85].  Domoic  acid  also  activates  AMPA-type  
receptors [201]. 
Dysiserbaine  is  a  neuroexcitotoxic  amino  acid  isolated  from  the  Micronesian  marine  sponge 
Dysidea  herbacea.  Dysiserbaine  is  another  kainate-receptors  specific  molecule  that  is  structurally 
unrelated to Kainoids [85]. 
Concanavalin A is a plant lectin isolated from jack bean (Canavalia ensiformis) [202]. It was 
found to be a positive allosteric modulator [203].  
8. P2X Receptors 
-Conotoxin GVIA has first been known to be a N-type calcium channel blocker [204]. It was 
latter shown to be also a potent inhibitor of P2X3 and P2X2/X3 receptors [205]. The observation that Toxins 2011, 3                        
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they  move  dose-response  curves  to  higher  ATP  concentrations  without  affecting  gating  kinetics 
suggests that it is a non-competitive inhibitor [205]. 
-Hemolysin promotes the formation of pore leading to hemolysis [206]. As P2X7 are known to 
open large pores their involvement has been tested. It was shown that -Hemolysin effect involves 
P2X1 and P2X7 [206]. It might be speculated that this cytotoxic activity is related to cell death routes 
involving P2X receptors. In a related manner, Porphyromonas gingivalis toxicity requires the secretion 
of an ATP-consumption enzyme to prevent apoptosis [207]. 
Endotoxin. Lipopolysaccharides have been shown to increase levels of P2X4/P2X7 expression in 
mouse hypocampus [208]. It was suggested that P2X receptors might have a role in IL-1 release [208] 
in addition to Toll-like receptor 4 [209]. Indirect effect of LPS could also be through modification of 
ATP levels [210].  
Maitotoxin was first proposed to act on P2X7 receptors because pores opened by maitotoxin could 
not be differenciated from those induced by the agonist Bz-ATP [211]. Thanks to variations in buffers 
and antagonists it was latter found that the effect is complementary [212]. 
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